The researchers believe their findings could be used to change how patients' risk for breast cancer, colon cancer, or heart disease is calculated.
Researchers found that about 12 percent to 15 percent of breast cancer patients carry multiple mutations in the gene, 95 percent of which are double mutations.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
AlloSure 3.0 can diagnose the very early stages of T-cell mediated rejection, allowing clinicians to begin anti-rejection therapies and monitor treatment.
Two new grants are helping the company develop its SHERLOCK and INSPECTR technologies as the basis for creating innovative diagnostics.
The company released new data showing that Cologuard 2.0 can detect colorectal cancer with higher sensitivity than the current version of the test.
The company's platform is based on nucleotide deamination, a process that occurs naturally in cells and doesn't create a permanent edit in the genome.
The prime editing technique has strengths that are complementary to nuclease-based editing and base editing.
The system uses the Cas13 nuclease to identify target sites in various RNA viruses and then destroy them.
The team identified six independent DNA methylation blocks that could potentially help to predict the formation of central nervous system metastases in lung cancer.
In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.
Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.